Section Arrow
CGEN.NASDAQ
- Compugen Ltd
Quotes are at least 15-min delayed:2024/05/15 20:23 EDT
Last
 2.21
+0.12 (+5.74%)
Day High 
2.2199 
Prev. Close
2.09 
1-M High
2.245 
Volume 
312.75K 
Bid
2.13
Ask
2.24
Day Low
2.08 
Open
2.08 
1-M Low
1.8301 
Market Cap 
187.12M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.1 
20-SMA 2.01 
50-SMA 2.31 
52-W High 3.0301 
52-W Low 0.53 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.21/-0.50
Enterprise Value
187.84M
Balance Sheet
Book Value Per Share
0.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
33.46M
Operating Revenue Per Share
0.08
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed:2024/05/15 20:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.